Dynavax Technolo Stock Price, News & Analysis

Dynavax Technologies Corporation (Nasdaq: DVAX) will announce its first quarter 2023 financial results on May 2, 2023, after U.S. market close. The company will host a conference call and live audio webcast at 4:30 p.m. ET to discuss these results.

Dynavax is known for its commercial-stage biopharmaceutical products, including the HEPLISAV-B® vaccine for hepatitis B and the CpG 1018® adjuvant used in COVID-19 vaccines. The company's focus includes advancing its adjuvant for various vaccines, including shingles and universal influenza. Further details can be found on their website.

Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on innovative vaccines, announced that Kelly MacDonald, CFO, will participate in a fireside chat at the Cowen 43rd Annual Health Care Conference on March 8, 2023, at 2:10 p.m. E.T. The presentation will be available via webcast on the company's investors page. Dynavax markets two key products: the HEPLISAV-B vaccine for hepatitis B and the CpG 1018 adjuvant used in COVID-19 vaccines. The company is also advancing clinical programs for shingles and influenza vaccines.

Dynavax Technologies Corporation (Nasdaq: DVAX) announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted Marketing Authorization for HEPLISAV B, a two-dose adult hepatitis B vaccine, in Great Britain. The approval is based on positive safety and immunogenicity results from three Phase 3 clinical trials. HEPLISAV B is designed to provide active immunization against various subtypes of hepatitis B virus in adults aged 18 and older, marking a significant advancement in hepatitis B prevention. Dynavax aims to engage potential commercial partners for distribution in Great Britain.

Dynavax Technologies Corporation (Nasdaq: DVAX) reported a strong financial performance for 2022, with total revenue reaching $723 million, a 64% increase from $439 million in 2021. The net revenue from HEPLISAV-B® vaccine was $126 million, up 104% year-over-year, while CpG 1018® adjuvant revenue hit $588 million. For 2023, the company expects HEPLISAV-B revenue between $165 million and $185 million, reflecting a 30-47% growth. The company ended the year with a robust cash position of $624 million.

Dynavax is well-positioned to capture a larger market share in the expanding adult hepatitis B vaccination landscape.

Dynavax Technologies Corporation (Nasdaq: DVAX) is set to announce its fourth quarter and full year 2022 financial results on February 23, 2023, after the U.S. market closes. A conference call will follow at 4:30 p.m. ET. Investors can access the live audio webcast through the company's website. Dynavax focuses on developing and commercializing innovative vaccines. Its notable products include HEPLISAV-B for Hepatitis B prevention and CpG 1018, used in various COVID-19 vaccines. The company aims to advance its position through global collaborations.

Dynavax Technologies Corporation announced its uplisting to the Nasdaq Global Select Market, effective January 31, 2023. This upgrade reflects the company's strong growth and adherence to strict financial standards. CEO Ryan Spencer stated that this advancement underscores the company's execution excellence and commitment to public health through innovative vaccines. Dynavax is recognized for its commercial products, including HEPLISAV-B, a hepatitis B vaccine, and CpG 1018, an adjuvant used in multiple COVID-19 vaccines. The Nasdaq Global Select Market includes over 1,700 stocks meeting rigorous corporate governance and financial requirements.

Dynavax Technologies (DVAX) reported strong preliminary financial results for the year ending December 31, 2022. HEPLISAV-B vaccine's net product revenue reached approximately $126 million, marking a 104% growth year-over-year. The CpG 1018 adjuvant generated about $588 million in revenue. The company maintained a robust cash position with approximately $624 million in cash and investments. Additionally, topline results from the Phase 1 shingles trial indicated favorable tolerability and promising vaccine response rates compared to the comparator vaccine, Shingrix®.